The Wilms’ tumor gene WT1 −17AA/−KTS splice variant increases tumorigenic activity through up-regulation of vascular endothelial growth factor in an in vivo ovarian cancer model

Keiko Yamanouchi, Tsuyoshi Ohta, Zhiyang Liu, Yusuke Oji, Haruo Sugiyama, Vijayalakshmi Shridhar, Sohei Matsumura, Toshifumi Takahashi, Kazuhiro Takahashi, Hirohisa Kurachi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

TheWilms' tumor 1 gene WT1 encodes a zinc transcription factor involved in a variety of cancer-related processes. In this study, we sought to investigate the effects ofWT1 splice variants on tumorigenic activity and survival in an in vivo ovarian cancermodel. To this end, we established stable ovarian cancer cell lines transduced with lentiviral constructs containing each of the four WT1 splice variants (−17AA/−KTS, +17AA/−KTS, −17AA/+KTS, and +17AA/+KTS). Inmice inoculated intraperitoneally with SKOV3ip1 cells expressingWT1 −17AA/−KTS, disseminated tumor weights and production of asciteswere significantly increased compared with those inmice inoculatedwith cells expressing the control vector. The overall survival inmice inoulatedwithWT1−17AA/−KTS-expressing cells was significantly shorter than that in mice inoculated with control cells (P =.0115). Immunoblot analysis revealed that WT1 −17AA/−KTS significantly increased the expression of vascular endothelial growth factor (VEGF) compared with the control. Greater numbers of CD31-immunopositive vessels were observed in tumors from mice injected with cells expressing WT1 −17AA/−KTS than in tumors from control mice. Finally, WT1 −17AA/−KTS significantly increased tumor microvessel density compared with that in the control (P b.05). Treatment with anti-VEGF antibody (bevacizumab) inhibited tumor growth, dissemination, and ascites production in mice injected with cells expressingWT1−17AA/−KTS. The overexpression ofWT1 −17AA/−KTS induced a more aggressive phenotype in ovarian cancer cells through VEGF up-regulation in an in vivo ovarian cancer model. Our findings indicated thatWT1 −17AA/−KTS enhanced tumorigenic activity and could decreased patient survival through up-regulation of VEGF expression in ovarian cancers.

Original languageEnglish (US)
Pages (from-to)580-589
Number of pages10
JournalTranslational Oncology
Volume7
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Wilms' Tumor Genes
Ovarian Neoplasms
Vascular Endothelial Growth Factor A
Up-Regulation
Neoplasms
Survival
Microvessels
Tumor Burden
Ascites
Zinc
Transcription Factors
Phenotype
Cell Line
Antibodies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The Wilms’ tumor gene WT1 −17AA/−KTS splice variant increases tumorigenic activity through up-regulation of vascular endothelial growth factor in an in vivo ovarian cancer model. / Yamanouchi, Keiko; Ohta, Tsuyoshi; Liu, Zhiyang; Oji, Yusuke; Sugiyama, Haruo; Shridhar, Vijayalakshmi; Matsumura, Sohei; Takahashi, Toshifumi; Takahashi, Kazuhiro; Kurachi, Hirohisa.

In: Translational Oncology, Vol. 7, No. 5, 2014, p. 580-589.

Research output: Contribution to journalArticle

Yamanouchi, Keiko ; Ohta, Tsuyoshi ; Liu, Zhiyang ; Oji, Yusuke ; Sugiyama, Haruo ; Shridhar, Vijayalakshmi ; Matsumura, Sohei ; Takahashi, Toshifumi ; Takahashi, Kazuhiro ; Kurachi, Hirohisa. / The Wilms’ tumor gene WT1 −17AA/−KTS splice variant increases tumorigenic activity through up-regulation of vascular endothelial growth factor in an in vivo ovarian cancer model. In: Translational Oncology. 2014 ; Vol. 7, No. 5. pp. 580-589.
@article{50389dbb6eac4adda979f8ba505bd918,
title = "The Wilms’ tumor gene WT1 −17AA/−KTS splice variant increases tumorigenic activity through up-regulation of vascular endothelial growth factor in an in vivo ovarian cancer model",
abstract = "TheWilms' tumor 1 gene WT1 encodes a zinc transcription factor involved in a variety of cancer-related processes. In this study, we sought to investigate the effects ofWT1 splice variants on tumorigenic activity and survival in an in vivo ovarian cancermodel. To this end, we established stable ovarian cancer cell lines transduced with lentiviral constructs containing each of the four WT1 splice variants (−17AA/−KTS, +17AA/−KTS, −17AA/+KTS, and +17AA/+KTS). Inmice inoculated intraperitoneally with SKOV3ip1 cells expressingWT1 −17AA/−KTS, disseminated tumor weights and production of asciteswere significantly increased compared with those inmice inoculatedwith cells expressing the control vector. The overall survival inmice inoulatedwithWT1−17AA/−KTS-expressing cells was significantly shorter than that in mice inoculated with control cells (P =.0115). Immunoblot analysis revealed that WT1 −17AA/−KTS significantly increased the expression of vascular endothelial growth factor (VEGF) compared with the control. Greater numbers of CD31-immunopositive vessels were observed in tumors from mice injected with cells expressing WT1 −17AA/−KTS than in tumors from control mice. Finally, WT1 −17AA/−KTS significantly increased tumor microvessel density compared with that in the control (P b.05). Treatment with anti-VEGF antibody (bevacizumab) inhibited tumor growth, dissemination, and ascites production in mice injected with cells expressingWT1−17AA/−KTS. The overexpression ofWT1 −17AA/−KTS induced a more aggressive phenotype in ovarian cancer cells through VEGF up-regulation in an in vivo ovarian cancer model. Our findings indicated thatWT1 −17AA/−KTS enhanced tumorigenic activity and could decreased patient survival through up-regulation of VEGF expression in ovarian cancers.",
author = "Keiko Yamanouchi and Tsuyoshi Ohta and Zhiyang Liu and Yusuke Oji and Haruo Sugiyama and Vijayalakshmi Shridhar and Sohei Matsumura and Toshifumi Takahashi and Kazuhiro Takahashi and Hirohisa Kurachi",
year = "2014",
doi = "10.1016/j.tranon.2014.07.008",
language = "English (US)",
volume = "7",
pages = "580--589",
journal = "Translational Oncology",
issn = "1936-5233",
publisher = "Neoplasia Press",
number = "5",

}

TY - JOUR

T1 - The Wilms’ tumor gene WT1 −17AA/−KTS splice variant increases tumorigenic activity through up-regulation of vascular endothelial growth factor in an in vivo ovarian cancer model

AU - Yamanouchi, Keiko

AU - Ohta, Tsuyoshi

AU - Liu, Zhiyang

AU - Oji, Yusuke

AU - Sugiyama, Haruo

AU - Shridhar, Vijayalakshmi

AU - Matsumura, Sohei

AU - Takahashi, Toshifumi

AU - Takahashi, Kazuhiro

AU - Kurachi, Hirohisa

PY - 2014

Y1 - 2014

N2 - TheWilms' tumor 1 gene WT1 encodes a zinc transcription factor involved in a variety of cancer-related processes. In this study, we sought to investigate the effects ofWT1 splice variants on tumorigenic activity and survival in an in vivo ovarian cancermodel. To this end, we established stable ovarian cancer cell lines transduced with lentiviral constructs containing each of the four WT1 splice variants (−17AA/−KTS, +17AA/−KTS, −17AA/+KTS, and +17AA/+KTS). Inmice inoculated intraperitoneally with SKOV3ip1 cells expressingWT1 −17AA/−KTS, disseminated tumor weights and production of asciteswere significantly increased compared with those inmice inoculatedwith cells expressing the control vector. The overall survival inmice inoulatedwithWT1−17AA/−KTS-expressing cells was significantly shorter than that in mice inoculated with control cells (P =.0115). Immunoblot analysis revealed that WT1 −17AA/−KTS significantly increased the expression of vascular endothelial growth factor (VEGF) compared with the control. Greater numbers of CD31-immunopositive vessels were observed in tumors from mice injected with cells expressing WT1 −17AA/−KTS than in tumors from control mice. Finally, WT1 −17AA/−KTS significantly increased tumor microvessel density compared with that in the control (P b.05). Treatment with anti-VEGF antibody (bevacizumab) inhibited tumor growth, dissemination, and ascites production in mice injected with cells expressingWT1−17AA/−KTS. The overexpression ofWT1 −17AA/−KTS induced a more aggressive phenotype in ovarian cancer cells through VEGF up-regulation in an in vivo ovarian cancer model. Our findings indicated thatWT1 −17AA/−KTS enhanced tumorigenic activity and could decreased patient survival through up-regulation of VEGF expression in ovarian cancers.

AB - TheWilms' tumor 1 gene WT1 encodes a zinc transcription factor involved in a variety of cancer-related processes. In this study, we sought to investigate the effects ofWT1 splice variants on tumorigenic activity and survival in an in vivo ovarian cancermodel. To this end, we established stable ovarian cancer cell lines transduced with lentiviral constructs containing each of the four WT1 splice variants (−17AA/−KTS, +17AA/−KTS, −17AA/+KTS, and +17AA/+KTS). Inmice inoculated intraperitoneally with SKOV3ip1 cells expressingWT1 −17AA/−KTS, disseminated tumor weights and production of asciteswere significantly increased compared with those inmice inoculatedwith cells expressing the control vector. The overall survival inmice inoulatedwithWT1−17AA/−KTS-expressing cells was significantly shorter than that in mice inoculated with control cells (P =.0115). Immunoblot analysis revealed that WT1 −17AA/−KTS significantly increased the expression of vascular endothelial growth factor (VEGF) compared with the control. Greater numbers of CD31-immunopositive vessels were observed in tumors from mice injected with cells expressing WT1 −17AA/−KTS than in tumors from control mice. Finally, WT1 −17AA/−KTS significantly increased tumor microvessel density compared with that in the control (P b.05). Treatment with anti-VEGF antibody (bevacizumab) inhibited tumor growth, dissemination, and ascites production in mice injected with cells expressingWT1−17AA/−KTS. The overexpression ofWT1 −17AA/−KTS induced a more aggressive phenotype in ovarian cancer cells through VEGF up-regulation in an in vivo ovarian cancer model. Our findings indicated thatWT1 −17AA/−KTS enhanced tumorigenic activity and could decreased patient survival through up-regulation of VEGF expression in ovarian cancers.

UR - http://www.scopus.com/inward/record.url?scp=84915753315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84915753315&partnerID=8YFLogxK

U2 - 10.1016/j.tranon.2014.07.008

DO - 10.1016/j.tranon.2014.07.008

M3 - Article

AN - SCOPUS:84915753315

VL - 7

SP - 580

EP - 589

JO - Translational Oncology

JF - Translational Oncology

SN - 1936-5233

IS - 5

ER -